Literature DB >> 31940469

Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome.

Karoline Krause1, Hanna Bonnekoh2, André Ellrich2, Athanasios Tsianakas3, Nicola Wagner4, Jörg Fischer5, Marcus Maurer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31940469     DOI： 10.1016/j.jaci.2019.12.909

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  4 in total

1.  Monoclonal gammopathies of clinical significance.

Authors:  Angela Dispenzieri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Diagnosis and management of monoclonal gammopathy of clinical significance.

Authors:  Hyungwoo Cho
Journal:  Blood Res       Date:  2022-04-30

Review 3.  New insights on multigenic autoinflammatory diseases.

Authors:  Petros Efthimiou; Olga Petryna; Priscila Nakasato; Apostolos Kontzias
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-03       Impact factor: 3.625

Review 4.  Efficacy of interleukin-1 blockade in Schnitzler's syndrome without detectable monoclonal gammopathy: a case-based review.

Authors:  Riccardo Bixio; Maurizio Rossini; Alessandro Giollo
Journal:  Clin Rheumatol       Date:  2020-11-11       Impact factor: 2.980
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.